Toxicology firm to offer antibody testing for COVID-19 in Indy, Carmel
The northwest side company said it has secured an FDA-approved serology test developed by Abbott Laboratories, making it the latest player to offer the service.
The northwest side company said it has secured an FDA-approved serology test developed by Abbott Laboratories, making it the latest player to offer the service.
The Indianapolis-based hospital system is feeling the effects of the COVID-19 pandemic. It also lost $201.2 million on investments during the quarter as the economy and financial markets tanked.
The Indianapolis-based company is expanding operations and trying to hire an additional 30 assembly workers to keep up with skyrocketing orders from the COVID-19 pandemic.
The partnership marks at least the fourth program Lilly is pursuing to find treatments for COVID-19, a disease that has claimed more than 249,000 lives worldwide, including more than 68,000 in the U.S.
Across Indiana, local health departments have been scrambling to keep up with the job of tracking, one patient at a time, the spread of the virus that has already claimed the lives of more than 900 Hoosiers.
By outsourcing the job to Virginia-based Maximus Inc., Indiana health officials hope to take the burden off of local health departments for the time-consuming job of contacting all COVID patients and learning who they might have exposed.
Gov. Eric Holcomb lifted the ban effective Monday, with some caveats, such as making sure that hospitals keep enough personnel and personal protective equipment on hand for COVID-19 patients.
Dr. Cole Beeler knows people are itching to get back to business and resume their normal lives. But he warns employers and workers not to rush back to the old way of doing business, at least not all at once.
The number of surgeries and inpatient discharges fell by more than 7% as Gov. Eric Holcomb ordered all hospitals to delay non-essential and elective surgeries and procedures.
The Indianapolis-based drugmaker, which reported quarterly earnings Thursday, warned it could feel the effects of rising unemployment, a decrease in new prescriptions, and downward pricing pressure from government health care systems.
The Indianapolis drugmaker said worldwide volume growth in the first quarter was boosted by “increased customer buying patterns and patient prescription trends” stemming from the pandemic.
Gov. Eric Holcomb said Monday the state would re-evaluate whether to allow hospitals and surgery centers to resume services at 11:59 p.m. Sunday if they have sufficient protective equipment for treating COVID-19 patients.
The two technologies are different, but the goal of both is to provide a result within 40 minutes. The researchers say they are working with manufacturers to develop the products, which they hope will retail for $5 or less.
Health officials examined about 8,000 coronavirus cases in Indiana and found about one-third visited an emergency room and about a quarter were hospitalized.
For years, Indiana has struggled to get sufficient funds and equipment for its public health efforts. Now, it’s in the biggest health crisis in decades and is trying to make do with funding that ranks among the lowest in the nation.
The figures reflect the outsized danger of the coronavirus to elderly people, who often are physically weak and have underlying conditions, from heart disease to diabetes.
Indiana University Health said admissions of COVID-19 patients at its 16 hospitals have been “pretty flat” over the past six or seven days, but it’s unclear whether the surge has peaked.
Nursing homes are now permitted to relocate or discharge residents to reduce the risk of COVID-19, even if families or local officials object, according to an order issued Tuesday by Indiana State Health Commissioner Kristina Box.
Baricitinib, also known under the brand name Olumiant, is approved in more than 65 countries as a treatment for adults with moderately to severely active rheumatoid arthritis.
The latest model from the Institute for Health Metrics and Evaluation now indicates hospitalizations from COVID-19 in Indiana crested last week. It also predicts that far fewer Hoosiers will die from the disease than estimated earlier.